Keywords: osi, shares, jump, tarceva/avastin, benefit, nsclc, phase

OSI shares jump 11.4% on Tarceva/Avastin benefit in NSCLC

Article | 09 February 2009

Print This

A Phase III study testing Swiss drug major Roche's Tarceva (erlotinib) plus Avastin (bevacizumab) has been stopped early because of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in